Two independent epigenetic biomarkers predict survival in neuroblastoma
Yania Yáñez(Hospital Universitari i Politècnic La Fe), Victoria Castel, Elena Grau(Hospital Universitari i Politècnic La Fe), Vanessa Segura(Universitat de València), Adela Cañete(Universitat de València), Virginia Rodríguez-Cortez(Institut d'Investigació Biomédica de Bellvitge), Rosa Noguera(Universitat de València), Jaime Font de Mora(Bellvitge University Hospital), Miguel Ángel Ibáñez-Hernández(Instituto Profesional La Araucana), Ana Conesa(Centro de Investigacion Principe Felipe), Enrique Vidal(Leitat Technological Center), David Hervás(Universitat Politècnica de València)
Cited by 33
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
|Journal of Clinical Oncology|1993|2.3k
Differential expression in RNA-seq: A matter of depth
|Genome Research|2011|1.7k
A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium
|Nature Biotechnology|2014|1.1k
Data quality aware analysis of differential expression in RNA-seq with NOISeq R/Bioc package
|Nucleic Acids Research|2015|843